Bruker Corporation Executive is Named Finance Chief at Quanterix
Quanterix Corporation has appointed Jason Faessler, formerly of Bruker Corporation, as its new chief financial officer. Faessler's extensive experience in finance leadership within the life science tools industry is expected to be crucial for Quanterix's future growth. He previously held senior financial roles at PAREXEL, EMC (now Dell), and Harvard Business Publishing.
Quanterix (QTRX) director adds 3,955 shares via RSU vest
Quanterix Corp (QTRX) director Jeffrey Thomas Elliott converted 3,955 restricted stock units (RSUs) into common stock on August 19, 2026, increasing his direct common stock holdings to 15,345 shares. He still holds 4,075 RSUs from an original grant of 11,985 RSUs issued on August 19, 2024, which vest over three years. This transaction was an exercise/conversion of a derivative security and not an open-market purchase or sale.
Quest Diagnostics Executive Recruited to Quanterix’s Senior Management Team
Quanterix Corporation has appointed Geoff Albrecht, formerly of Quest Diagnostics, as Senior Vice President and General Manager of Diagnostics. Albrecht will lead Quanterix’s Diagnostics strategy, focusing initially on Alzheimer's Disease Diagnostics, and will be responsible for scaling the company's diagnostics portfolio into a significant revenue driver. This hire emphasizes Quanterix's commitment to making diagnostics a core part of its future growth, leveraging Albrecht's 25 years of commercial leadership experience.
Quanterix (QTRX) director now holds 162,401 shares
Quanterix Corp (QTRX) director William P. Donnelly reported the vesting and conversion of 2,802 restricted stock units (RSUs) into common stock on August 17, 2026. Following this transaction, Donnelly directly holds 162,401 shares of Quanterix common stock. The RSUs were originally granted on August 17, 2023, with a three-year vesting schedule.
Quanterix (QTRX) CCO files initial ownership report with no shares
James Edward Gute Jr., Chief Commercial Officer of Quanterix Corp (QTRX), has filed an initial statement of beneficial ownership of securities (Form 3) with no current reportable holdings or transactions in Quanterix Corp securities. This filing indicates that as of the report date, he does not beneficially own any shares of the company, serving as an initial inventory sheet for his insider status. The document also details the specifics of the Form 3 filing, including the date of event and reporting person's information.
Quanterix files Form 3 for Chief Commercial Officer James Edward Gute Jr
Quanterix has filed a Form 3 for James Edward Gute Jr., officially naming him as Chief Commercial Officer. The filing was dated August 17, 2026. This news brief was generated by AI based on information from the SEC's EDGAR system.
Quanterix (QTRX) CTO converts RSUs, withholds shares for taxes
Quanterix Corp's CTO, Michael Francis Miller, recently converted 1,558 restricted stock units (RSUs) into common stock and had 467 shares withheld for tax liabilities at $2.59 per share. This transaction, filed on August 15, 2026, is largely administrative, reflecting equity compensation rather than market activity. Miller's holdings now include 36,791 RSUs and 37,250 common stock shares directly.
Quanterix (NASDAQ:QTRX) Price Target Cut to $3.00 by Analysts at Canaccord Genuity Group
Canaccord Genuity Group has reduced its price target for Quanterix (NASDAQ:QTRX) from $4.00 to $3.00, while maintaining a "hold" rating, suggesting a potential upside of 15.8% from its current price. This cut follows Quanterix missing analyst expectations in its latest quarterly earnings, reporting a loss of $1.04 per share against an anticipated $0.41 loss and revenues of $32.91 million versus a $37.48 million consensus. The company currently holds an average "Reduce" rating from analysts with a consensus price target of $3.00.
Canaccord cuts Quanterix stock price target on weak Q2 results
Canaccord has lowered its price target for Quanterix Corp. (NASDAQ:QTRX) to $3.00 from $4.00, while maintaining a Hold rating, due to weaker-than-expected Q2 2026 results and ongoing commercial execution challenges. The company's stock has seen a significant decline, burning through cash, despite progress in Alzheimer’s diagnostics and an InvestingPro analysis suggesting undervaluation. Quanterix reported Q2 revenue of $32.9 million, below consensus estimates, and announced organizational changes to address its performance issues.
Canaccord cuts Quanterix stock price target on weak Q2 results By Investing.com
Canaccord has reduced its price target for Quanterix Corp. (NASDAQ:QTRX) from $4.00 to $3.00, maintaining a Hold rating, following the company's weaker-than-expected second-quarter 2026 results. The stock has seen a significant decline, reflecting investor concerns over commercial execution challenges and cash burn, despite some progress in Alzheimer's diagnostics. Quanterix reported Q2 revenue of $32.9 million, missing consensus estimates, and announced organizational changes to address these issues.
Quanterix (QTRX) Q2 2026 Earnings Call Transcript
Quanterix reported Q2 2026 earnings, revealing a revenue of $32.9 million, a 34% increase year-over-year but a 23% pro forma decline. The company lowered its full-year 2026 revenue guidance to $142 million-$148 million due to commercial execution challenges and market softness, pushing back its cash flow break-even target to 2027. Despite these challenges, Quanterix is reorganizing its commercial team, making strategic investments in its Alzheimer’s disease diagnostics business, and announced new leadership appointments to drive improved performance in the second half of 2026 and beyond.
Executive Chair of Quanterix Picks Up 62% More Stock
Quanterix Corporation's Executive Chair, William P. Donnelly, recently purchased US$286k worth of the company's stock at US$2.88 per share, increasing his holding by 62%. This transaction represents the largest insider purchase in the last year, suggesting confidence in the company's future despite it not having made a profit in the last twelve months. Insiders own 6.8% of the company, and while not considered high, the transaction history indicates optimism.
Quanterix Reshapes Sales Strategy, Targets Q4 FDA Decision for Alzheimer’s Blood Test
Quanterix (NASDAQ: QTRX) is restructuring its sales organization into specialized teams for spatial biology, Simoa products, and clinical-trial services to improve commercial execution. The company is targeting a Q4 FDA decision for its LucentAD Complete Alzheimer's blood test, with a goal of achieving $10 million in diagnostics revenue in 2026. Despite continued pressures in academic and biopharma markets, Quanterix aims to stabilize its research tools business and has pushed its cash-flow breakeven target to next year.
Quanterix Reshapes Sales Strategy, Targets Q4 FDA Decision for Alzheimer’s Blood Test
Quanterix is reorganizing its sales teams into specialized units for spatial biology, Simoa products, and clinical-trial services to improve commercial execution. The company is also aiming for an FDA decision on its LucentAD Complete Alzheimer’s blood test by Q4, with a goal of achieving $10 million in diagnostics revenue in 2026. Despite academic and biopharma funding pressures, Quanterix anticipates flat revenue in Q3 before sequential improvement in Q4, though its cash-flow breakeven target has been pushed to next year.
Quanterix (NASDAQ:QTRX) Lowered to Sell Rating by Wall Street Zen
Wall Street Zen has downgraded Quanterix (NASDAQ:QTRX) from a "Hold" to a "Sell" rating, while other analysts maintain "Hold" ratings, leading to an overall "Reduce" consensus and an average price target of $3.50. The company's shares opened significantly lower at $2.59, trading below key moving averages, and recently missed analyst expectations for both earnings and revenue in its latest quarterly report. Institutional investors have also adjusted their positions in the life sciences and diagnostics company.
Quanterix Corp (QTRX) director-linked trusts buy 99,400 shares in open market
Quanterix Corp (QTRX) director William P. Donnelly, through trusts, indirectly purchased a total of 99,400 common shares in open-market transactions on August 12 and 13, 2026. The purchases were made at weighted average prices of $2.75 and $2.93 per share, respectively, totaling approximately $286,000. These transactions were disclosed in a Form 4 filing, indicating a positive sentiment and moderate filing impact.
Quanterix Insider Bought Shares Worth $286,354, According to a Recent SEC Filing
An insider at Quanterix Corporation (QTRX) recently purchased shares valued at $286,354, according to a new SEC filing. This transaction was published on August 14, 2026, at 04:11 pm EDT. The article also provides recent news on Quanterix, including their Q2 2026 earnings results and revised financial guidance.
Earnings Update: Quanterix Corporation (NASDAQ:QTRX) Just Reported And Analysts Are Trimming Their Forecasts
Quanterix Corporation recently reported disappointing second-quarter results, with revenues falling 12% short of analyst estimates and statutory losses significantly exceeding expectations. Following this, analysts have made serious cuts to their revenue outlook for 2026, now expecting a 6.8% decline, and anticipate increased losses per share. The average price target has also fallen by 23%, indicating greater pessimism about the company's intrinsic value and future performance compared to the wider industry.
Quanterix (QTRX) Earnings Shake Up The Story As Fair Value Still Sits Higher
Quanterix (QTRX) recently released its Q2 2026 earnings report, showing higher revenue but a wider net loss and a lowered full-year revenue outlook, alongside the appointment of a new Chief Commercial Officer. Despite these mixed results, the stock saw a brief rebound, suggesting investors are re-evaluating its potential. Simply Wall St's analysis indicates Quanterix is currently undervalued, with a fair value of $4.33 against a closing price of $2.63, driven by an expanded addressable market through the combined Quanterix Akoya entity.
TD Cowen Issues Pessimistic Forecast for Quanterix (NASDAQ:QTRX) Stock Price
TD Cowen has lowered its price target for Quanterix (NASDAQ:QTRX) from $4.00 to $3.00, maintaining a "hold" rating due to the company's recent earnings and revenue misses. The stock, currently trading near its 52-week low at $2.48, holds an average analyst rating of "Reduce" with a consensus target price of $3.50. Quanterix reported a quarterly loss of $1.04 per share against an estimated loss of $0.41, and revenue of $32.91 million fell short of the $37.46 million forecast.
Quanterix 2Q Rev $32.9M >QTRX
This article provides a brief update on Quanterix's Q2 revenue. The company reported revenue of $32.9 million, surpassing analyst expectations. This financial update indicates a positive performance for Quanterix during the second quarter.
Quanterix Cuts 2026 Revenue Outlook as Commercial Challenges Delay Cash-Flow Break-Even
Quanterix has lowered its 2026 revenue forecast and pushed its cash-flow break-even target to 2027 due to weaker-than-expected commercial performance and execution challenges. The company reported 34% revenue growth in Q2 2026 but reduced its full-year outlook by $21-$27 million and expects year-end cash to be $80 million, down from $100 million previously. In response, Quanterix is reorganizing commercial operations and strengthening leadership while continuing its focus on Alzheimer's diagnostics.
Earnings call transcript: Quanterix Q2 2026 revenue miss sends shares down 43%
Quanterix reported Q2 2026 revenue of $32.9 million, significantly missing analyst expectations of $38.06 million and causing shares to drop 43%. The company revised its full-year 2026 revenue guidance downwards and pushed back its cash flow breakeven target to 2027, citing commercial execution issues and softness in academic and government spending. Despite challenges, Quanterix is reorganizing its sales force, investing in its diagnostics business, particularly the LucentAD Complete Alzheimer's test, and announced new leadership appointments to drive future growth.
Quanterix Corp (QTRX) Misses Q2 Earnings Estimates with EPS at -$1.04 and Revenue of $32.9M; Is the Stock 65.9% Undervalued? GF Score: 63/100
Quanterix Corp (QTRX) reported its Q2 2026 financial results, missing analyst estimates with a revenue of $32.9 million against an expected $37.46 million, and an adjusted loss per share of $1.04 compared to a forecasted $0.40 loss. Despite challenges like market softness and execution issues, the company saw a 34% revenue increase year-over-year and improved its adjusted EBITDA loss and cash preservation. GuruFocus data indicates QTRX is significantly undervalued by 65.9%, with a GF Score of 63/100, suggesting a potential buying opportunity for value investors.
Quanterix Names Jim Gute Chief Commercial Officer to Accelerate Growth
Quanterix Corporation has appointed Jim Gute as Chief Commercial Officer to lead its commercial operations. Gute will focus on expanding the company's customer base, increasing the utilization of its installed systems, and strengthening commercial execution as Quanterix prepares to grow its diagnostics business and core research offerings. His experience from Exact Sciences and GE Healthcare will be instrumental in commercializing Quanterix's ultra-sensitive protein detection (Simoa) and spatial analysis technologies, particularly as the company moves into diagnostic applications and integrates its recent acquisition of Akoya Biosciences.
Quanterix Corp 2026: Revenue $32.91M, EPS ($1.04) — 10-Q Summary
Quanterix Corp (QTRX) reported its financial results for the quarter ended 2026, with revenues reaching $32.91 million and a net loss of $48.93 million, resulting in a diluted loss per share of $1.04. This represents a significant increase in revenue and net loss compared to the prior year quarter, largely driven by the acquisition of Akoya. The company also highlighted regulatory progress with an Alzheimer's blood test and operational achievements in integrating Akoya.
Quanterix (QTRX) boosts revenue as Alzheimer’s bets rise amid big write-downs
Quanterix reported a 34% increase in Q2 2026 revenue to $32.9 million, largely driven by the acquisition of Akoya Biosciences, but also recorded significant net losses of $48.9 million due to substantial goodwill and R&D impairments. The company is strategically shifting its focus towards Alzheimer's diagnostics, submitting a 510(k) for a multi-analyte blood test and securing Medicare and commercial coverage for its LucentAD Complete LDT, while also implementing cost synergies from the Akoya acquisition. Despite revenue growth, Quanterix anticipates continued operating losses into 2027 and plans further investments in commercial and diagnostic capabilities.
Quanterix Q2 2026 earnings: Revenue rises 34% as outlook is cut
Quanterix (QTRX) reported a 34% rise in Q2 2026 revenue to $32.9 million, primarily driven by product sales. Despite a narrower adjusted EBITDA loss, the GAAP net loss widened significantly to $48.9 million due to a $26.9 million Akoya-related goodwill impairment. The company cut its full-year guidance, citing execution challenges and market softness, and pushed its cash-flow breakeven target to 2027.
Quanterix Corp (QTRX) Stock News Today
This article provides an update on Quanterix Corp (QTRX) stock, noting a recent price increase of 5.22% to $4.030. It indicates that more news regarding earnings, analyst ratings, and key developments will be available soon. The page serves as a hub for financial information on QTRX.
Quanterix Corp (QTRX) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Quanterix Corp (QTRX), detailing its current earnings forecast score, average price target, and analyst ratings. Based on 3 analysts, the stock has a "Hold" rating with an average price target of $6.50, suggesting a potential upside of 16.80%. The article also includes expected revenue and EPS for upcoming quarters.
Earnings To Watch: Quanterix Corp (QTRX) Q2 2026 -- GF Value Sees 253% Upside
Quanterix Corp (QTRX) is set to release its Q2 2026 earnings on August 10, 2026, with revenue estimated at $37.46 million and an expected loss of $0.40 per share. While full-year 2026 revenue estimates have slightly declined, earnings estimates for 2027 have also seen a decrease. Analysts have an average "Hold" recommendation for QTRX with a 12-month target price of $4.33, while GuruFocus estimates a significant upside of 253.46% based on its GF Value of $13.52.
First Eagle Investment Management (QTRX) discloses 5.8% Quanterix ownership via advised funds
First Eagle Investment Management, LLC has reported a beneficial ownership of 2,753,165 shares, or 5.8% of Quanterix Corp (QTRX) common stock, as of June 30, 2026. These shares grant First Eagle sole voting and dispositive power. The First Eagle Small Cap Opportunity Fund, advised by First Eagle, accounts for 2,421,533 of these shares, representing 5.1% of Quanterix's common stock.
Quanterix CEO to give company update in Aug. 12 webcast
Quanterix Corporation (NASDAQ: QTRX) announced that its senior management will participate in the Canaccord Genuity Capital Markets 46th Annual Growth Conference on August 11-12, 2026. CEO Everett Cunningham will provide a company update during a live webcast fireside chat on August 12, and CTO Michael Miller will join a panel discussion on Neurology Diagnostics. The company will also hold one-on-one investor meetings at the event.
Quanterix To Participate in Canaccord Genuity Capital Markets 46th Annual Growth Conference on August 11-12
Quanterix Corporation announced that its senior management will participate in the Canaccord Genuity Capital Markets 46th Annual Growth Conference on August 11-12, 2026. CEO Everett Cunningham will present in a fireside chat, and Chief Technology and Product Officer Michael Miller will join a panel on Neurology Diagnostics. The management team, including CFO Jason Faessler, will also hold one-on-one investor meetings during the event.
Quanterix Corp (NASDAQ: QTRX) CTO reports 130 RSUs vesting, 39 shares withheld
Quanterix Corp's Chief Technology Officer, Michael Francis Miller, reported the conversion of 130 restricted stock units (RSUs) into common shares and the disposal of 39 shares at $3.48 each to cover tax liabilities on July 31, 2026. This transaction is part of a larger RSU grant from September 2022, with a specific vesting schedule. The filing indicates a neutral impact and sentiment, and these transactions were not affirmed under a Rule 10b5-1 trading plan.
Quanterix To Report Second Quarter 2026 Financial Results on August 10, 2026
The article announces that Quanterix will report its second-quarter 2026 financial results on August 10, 2026. This brief notice is embedded within a privacy consent page, indicating upcoming financial news for the company.
Quanterix will post its Q2 results before Aug. 10 call
Quanterix Corporation (Nasdaq: QTRX) announced it will host a conference call on Monday, August 10, 2026, at 8:30 AM ET to discuss its second quarter 2026 financial results. The company will issue a press release with these results prior to the call. Interested parties can access the call via dial-in or live webcast on the Quanterix investor relations website.
Quanterix Number of Employees 2026 | Employee Count & Headcount Data
Quanterix Corp. (NASDAQ: QTRX) had approximately 440 employees worldwide as of March 2026, marking a 31.6% decline from 643 employees in 2023. The company, headquartered in Billerica, Massachusetts, is actively hiring despite a 54.5% decline in active job postings in 2026 compared to 2025. The workforce is primarily concentrated in North America, with an average salary of $129,669.
Quanterix Corp (QTRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Quanterix Corp (QTRX), detailing its current price momentum score, support and resistance levels, and an overview of various technical indicators and moving averages. As of the analysis, QTRX has a price momentum score of 4.48 and is suitable for range-bound swing trading between resistance at $4.20 and support at $3.10. The technical indicators show a mixed signal with several "Sell" and "Neutral" calls, and moving averages predominantly signal "Sell."
Quanterix Corp (QTRX) Risk Assessment: Volatility, Financial Risk & Investment Risk
This article provides a risk assessment for Quanterix Corp (QTRX), highlighting its current risk score and industry ranking within the Healthcare Equipment & Supplies sector. It details the company's beta value, indicating its volatility relative to the S&P 500 index, and presents various financial metrics such as VaR, maximum drawdown, volatility, and historical daily returns. The assessment also covers liquidity measures like average turnover rate and turnover deviation.
Quanterix Corp (QTRX) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of Quanterix Corp (QTRX) from TradingKey. As of July 28, 2026, QTRX has a valuation score of 7.47, ranking 153 out of 199 in the Healthcare Equipment & Supplies industry. The company's current P/E ratio is -1.48, which is significantly below its recent high and above its recent low, though other key valuation metrics like P/B, P/S, and P/CF have not yet been disclosed.
Quanterix Corp (QTRX) Cash Flow
This article provides a detailed historical cash flow statement for Quanterix Corp (QTRX), including operating, investing, and financing cash flows, presented in a quarterly and annual format. It also offers definitions and explanations for key cash flow metrics such as operating cash flow, investing cash flow, financing cash flow, and free cash flow, along with specific figures for QTRX's recent performance. The data spans from FY2016Q1 to FY2026Q1, allowing for a comprehensive analysis of the company's financial soundness and stability over time.
QTRX|Quanterix Corp|Price:3.665|Chg%:-0.005
This article provides a detailed company profile for Quanterix Corp (QTRX), highlighting its business scope in ultra-sensitive biomarker detection using its Simoa technology. It includes financial data, market performance, executive information, and key insights into its revenue streams and institutional shareholdings. The company's technology supports research across various medical fields, and its main revenue comes from product sales.
Quanterix Corporation Revenue Breakdown – NASDAQ:QTRX
Quanterix Corporation (NASDAQ: QTRX) generated $138.90 million USD in revenue last year, primarily from its Ultra-sensitive Digital Immunoassay Platforms segment. North America was the largest contributor to revenue, accounting for $85.36 million USD. This information provides a snapshot of the company's financial performance by segment and geographic region.
Quanterix Corp (QTRX) Income Statement
This article provides a detailed quarterly and annual income statement for Quanterix Corp (QTRX), offering financial data from FY2016Q1 through FY2026Q1. It includes metrics like total revenue, cost of revenue, operating expenses, and net income, alongside year-over-year percentage changes. The report also features an FAQ section explaining how to read the income statement and highlighting key metrics for analyzing QTRX stock.
QTRX|Quanterix Corp|Price:3.670|Chg%:-0.250
This article provides a financial overview of Quanterix Corp (QTRX), detailing its earnings, revenue, and key financial indicators from FY2021Q2 to FY2026Q1, with a specific focus on FY2025 annual results. It highlights the company's EPS, net profit, revenue, and various balance sheet and cash flow items. The article notes the company's stock price, market cap, and an analyst rating of "HOLD".
QTRX|Quanterix Corp|Price:3.670|Chg%:-0.250
Quanterix Corp (QTRX) shows relatively healthy fundamentals and significant growth potential, although its stock price has been trending sideways. The company's valuation is considered fairly valued within the Healthcare Equipment & Supplies industry, and institutional ownership is notably high. Analysts currently rate the stock as "Hold" with a highest price target of $4.33, suggesting an expected upward trend in the medium term despite weak recent market performance.
QTRX|Quanterix Corp|Price:3.670|Chg%:-0.250
Quanterix Corp (QTRX) is trading at $3.67, experiencing a 6.38% dip. The company, which specializes in ultra-sensitive biomarker detection with its Simoa technology, is considered fairly valued with significant growth potential, although it faces risks like institutional selling and lower market activity. Analysts currently rate the stock as "Hold" with a target price of $4.333, indicating a potential upside space of 10.54%.
Biomarker Collaboration and Licensing Deals Report 2016-2026 - Featuring Quanterix, Caris Life Sciences, Alnylam Pharmaceuticals, Guardant Health, Eurofins Scientific and More
ResearchAndMarkets.com has released a comprehensive report titled "Biomarker Collaboration and Licensing Deals 2016-2026," which analyzes over 590 biomarker collaboration and licensing deals. This report aims to provide a clear understanding of how partnerships are structured, negotiated, and executed in the biomarker market, covering financial terms, contractual provisions, and active dealmakers. It serves as a benchmark for biomarker dealmaking, offering insights into market standards, valuation support, and strategic decision-making for companies like Quanterix, Caris Life Sciences, and Alnylam Pharmaceuticals.
Quanterix: Trading Below 1x Sales Despite A Changing Story (NASDAQ:QTRX)
Quanterix (QTRX) is undergoing a significant transformation under new management following the Akoya acquisition, aiming for cash flow breakeven in the second half of 2026. The company plans to achieve this through cost synergies, improved commercial execution, and leveraging its established base for recurring revenue. With potential growth drivers like the Alzheimer's blood test and its broader biomarker platform, the author assigns a buy rating, projecting substantial upside if management successfully executes its strategy.
